STOCK TITAN

SpringWorks Therapeutics Inc - SWTX STOCK NEWS

Welcome to our dedicated news page for SpringWorks Therapeutics (Ticker: SWTX), a resource for investors and traders seeking the latest updates and insights on SpringWorks Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SpringWorks Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SpringWorks Therapeutics's position in the market.

Rhea-AI Summary
SpringWorks Therapeutics (SWTX) initiates NDA submission for mirdametinib, an MEK inhibitor, for NF1-PN treatment. Positive Phase 2b trial data show significant response rates and patient-reported improvements. Orphan Drug and Fast Track designations granted by FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
none
-
Rhea-AI Summary
SpringWorks Therapeutics, Inc. announces the validation of the Marketing Authorization Application (MAA) for nirogacestat by the European Medicines Agency (EMA) for the treatment of desmoid tumors. Nirogacestat showed significant improvements in progression-free survival, objective response rate, and patient-reported outcomes in the Phase 3 DeFi trial, positioning it as a potential first therapy for desmoid tumors in the EU.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
none
-
Rhea-AI Summary
SpringWorks Therapeutics, Inc. reported $5.4 million in net product revenue for OGSIVEO in the first partial quarter post-FDA approval. They submitted a Marketing Authorization Application for nirogacestat for desmoid tumors in Europe. Positive Phase 2b ReNeu trial data for mirdametinib in NF1-PN was presented, with plans to submit an NDA in 2024. SW-682 IND was submitted and FDA cleared for Phase 1a trial. The company ended 2023 with $662.6 million in cash, cash equivalents, and marketable securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.41%
Tags
earnings
Rhea-AI Summary
SpringWorks Therapeutics, Inc. (SWTX) will present at investor conferences including TD Cowen 44th Annual Health Care Conference and Barclays 26th Annual Global Healthcare Conference. Webcasts will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
conferences
-
Rhea-AI Summary
SpringWorks Therapeutics, Inc. (SWTX) will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 8, 2024. The event will be held in New York, New York, at 2:00 p.m. ET. The live webcast can be accessed on the company's website, with a replay available for a limited time after the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
conferences
-
Rhea-AI Summary
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) presented its 2023 accomplishments and 2024 key milestones at the 42nd Annual J.P. Morgan Healthcare Conference, highlighting FDA approval for OGSIVEO, positive data from the Phase 3 DeFi trial of nirogacestat, and positive topline data from the Phase 2b ReNeu trial evaluating mirdametinib.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.4%
Tags
none
Rhea-AI Summary
SpringWorks Therapeutics, Inc. (SWTX) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
conferences
-
Rhea-AI Summary
SpringWorks Therapeutics, Inc. (SWTX) closed an underwritten public offering of 10,905,171 shares of its common stock at a public offering price of $29.00 per share, grossing approximately $316.25 million. The offering was managed by Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Cowen and Company, LLC, and Guggenheim Securities, LLC. The company's focus on severe rare diseases and cancer is evident from its strategic financial moves.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
-
Rhea-AI Summary
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) has announced the pricing of an underwritten public offering of 9,482,758 shares of its common stock at a public offering price of $29.00 per share. The gross proceeds from the offering are expected to be approximately $275.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.59%
Tags
offering
Rhea-AI Summary
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) has commenced an underwritten public offering of $250.0 million of shares of its common stock, with an additional option for underwriters to purchase up to $37.5 million more. The joint book-running managers for the offering are Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Cowen and Company, LLC, and Guggenheim Securities, LLC. The offering is subject to market and other conditions, and the company has filed an automatic shelf registration statement on Form S-3ASR with the SEC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.59%
Tags
offering
SpringWorks Therapeutics Inc

Nasdaq:SWTX

SWTX Rankings

SWTX Stock Data

3.63B
68.02M
2.88%
107.42%
15.14%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Stamford

About SWTX

springworks therapeutics is a mission-driven medicines company dedicated to developing innovative potential new treatments for unserved and underserved patient communities. originally conceived by pfizer, springworks presents a groundbreaking new model for collaboration rooted in connecting scientists, biopharmaceutical partners, patient groups, funders and philanthropists to advance and deliver transformative science to patients. through our partnerships, we remain focused on providing innovative treatments an additional avenue for development, with our launch pipeline focused on advancing potential programs for four diseases, all of which currently have no cure, including desmoid tumor, neurofibromatosis, hereditary xerocytosis and post-traumatic stress disorder. our name is a reflection of our approach to drug development: we’re springing into action to deliver treatments to people who are in great need and without alternatives.